Heat-Killed Bifidobacterium longum KABP-042 and Lactiplantibacillus Plantarum KABP-051 Prevent Scopolamine-Induced BDNF Reduction and Memory Impairment in Mice.
Confidence:
0.08
· 4 полей извлечено
Идентификация (6 полей)
Target
BDNF
0.90
Alt. target
—
0.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Heat-Killed Bifidobacterium longum KABP-042 and Lactiplantibacillus Plantarum KABP-051 Prevent Scopolamine-Induced BDNF Reduction and Memory Impairment in Mice; Symbiotic (L. acidophilus and Agave Inulin) Prevents Cognitive Impairment in High-Fat Diet/STZ Rats; Prebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson's disease by modulating butyrate-producing gut bacteria; Inulin ameliorates chronic ketamine-induced anxiety-like behaviors and impairments in spatial learning and memory: involvement of gut microbiota, microbial metabolite short-chain fatty acids, and the BDNF-TrkB-ERK1/2-CREB pathway; Probiotics reverse prenatal stress-induced anxiety and memory impairment in rats through gut-hippocampus axis regulation
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Mice; Rats
0.90
Diet/model
Scopolamine-induced model; High-Fat Diet/STZ; Parkinson's disease model; Chronic ketamine exposure; Prenatal stress model
0.90
Клиника (11 полей)
Drug
—
0.00
Indication
—
0.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00